Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Lisaftoclax by Ascentage Pharma Group International for Refractory Multiple Myeloma: Likelihood of Approval
Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Refractory Multiple Myeloma. According...
Lisaftoclax by Ascentage Pharma Group International for Relapsed Multiple Myeloma: Likelihood of Approval
Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Relapsed Multiple Myeloma. According...
Lisaftoclax by Ascentage Pharma Group International for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase III for Chronic Lymphocytic Leukemia (CLL)....
Lisaftoclax by Ascentage Pharma Group International for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Acute Myelocytic Leukemia (AML,...